Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
As a discount to earnings, iTeos ranks better than nearly 88% of the biotech industry.
Source: https://investorplace.com/2023/03/7-dirt-cheap-stocks-sitting-in-the-sweet-spot/
Cabaletta Bio currently has a consensus target price of $23.90, suggesting a potential upside of 86.72%. iTeos Therapeutics has a consensus target price of $36.33, suggesting a potential upside of 308.24%.